Evidence map›Paper›PMID 36460518›Full record

ArticleBritish journal of anaesthesia2023

Effect of intrathecal NIS-lncRNA antisense oligonucleotides on neuropathic pain caused by nerve trauma, chemotherapy, or diabetes mellitus.

Chun-Hsien Wen, Tolga Berkman, Xiang Li, Shibin Du, Gokulapriya Govindarajalu, Haijun Zhang, Alex Bekker, Steve Davidson, Yuan-Xiang Tao

Open access · greenAbstract read
In one paragraph

Article in British journal of anaesthesia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. RNA-binding protein MBNL2 mitigates neuropathic pain after chemotherapy through destabilizing CCR2 expression in primary sensory neurons.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Gene therapy for chronic pain management.Cell reports. Medicine · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chun-Hsien WenDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Tolga BerkmanDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Xiang LiDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Shibin DuDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Gokulapriya GovindarajaluDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Haijun ZhangDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Alex BekkerDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA.
Steve DavidsonDepartment of Anaesthesiology, Pain Research Centre, and Neuroscience Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Yuan-Xiang TaoDepartment of Anaesthesiology, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA; Department of Physiology, Pharmacology & Neuroscience, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA; Department of Cell Biology & Molecular Medicine, New Jersey Medical School, Rutgers, The State University of New Jersey, Newark, NJ, USA. Electronic address: yuanxiang.tao@njms.rutgers.edu.
Rutgers, The State University of New Jersey · USUniversity of Cincinnati Medical Center · US

Funding

Discovery and validation of a new long noncoding RNA as a novel target for neuropathic painRF1NS113881 · NINDS · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DAVIDSON, STEVE, TAO, YUAN-XIANG · 2019 to 2019
$3.5M
Role of dorsal root ganglion FTO, a RNA demethylase, in neuropathic painR01NS111553 · NINDS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI TAO, YUAN-XIANG · 2019 to 2023
$2.5M
Identification of a Novel DRG-Specific Long Noncoding RNA and its Role in Neuropathic PainR01NS117484 · NINDS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI HU, HUIJUAN, TAO, YUAN-XIANG · 2021 to 2025
$2.4M
NINDS NIH HHS R01 NS111553NINDS NIH HHS R01 NS117484NINDS NIH HHS RF1 NS113881
6 · The paper itself

Abstract

backgroundBlocking increased expression of nerve injury-specific long non-coding RNA (NIS-lncRNA) in injured dorsal root ganglia (DRG) through DRG microinjection of NIS-lncRNA small hairpin interfering RNA or generation of NIS-lncRNA knockdown mice mitigates neuropathic pain. However, these strategies are impractical in the clinic. This study employed a Food and Drug Administration (FDA)-approved antisense oligonucleotides strategy to examine the effect of NIS-lncRNA ASOs on neuropathic pain.

methodsEffects of intrathecal injection of NIS-lncRNA antisense oligonucleotides on day 7 or 14 after chronic constriction injury (CCI) of the sciatic nerve, fourth lumbar (L4) spinal nerve ligation, or intraperitoneal injection of paclitaxel or streptozotocin on the expression of DRG NIS-lncRNA and C-C chemokine ligand 2 (CCL2, an NIS-lncRNA downstream target) and nociceptive hypersensitivity were examined. We also assessed whether NIS-lncRNA antisense oligonucleotides produced cellular toxicity.

resultsIntrathecal NIS-lncRNA antisense oligonucleotides attenuated CCI-induced mechanical allodynia, heat hyperalgesia, cold hyperalgesia, and ongoing nociceptive responses, without changing basal or acute nociceptive responses and locomotor function. Intrathecal NIS-lncRNA antisense oligonucleotides also blocked CCI-induced increases in NIS-lncRNA and CCL2 in the ipsilateral L3 and L4 DRG and hyperactivities of neurones and astrocytes in the ipsilateral L3 and L4 spinal cord dorsal horn. Similar results were found in antisense oligonucleotides-treated mice after spinal nerve ligation or intraperitoneal injection of paclitaxel or streptozotocin. Normal morphologic structure and no cell loss were observed in the DRG and spinal cord of antisense oligonucleotides-treated mice.

conclusionThese findings further validate the role of NIS-lncRNA in trauma-, chemotherapy-, or diabetes-induced neuropathic pain and demonstrate potential clinical application of NIS-lncRNA antisense oligonucleotides for neuropathic pain management.

Indexed as

Diabetes MellitusNeuralgiaRNA, Long NoncodingAnimalsHyperalgesiaMiceOligonucleotides, AntisenseRatsRats, Sprague-DawleyRNA, Small InterferingSpinal Cord Dorsal HornStreptozocinOligonucleotides, AntisenseRNA, Long NoncodingRNA, Small InterferingStreptozocinantisense oligonucleotidesCCL2chemotherapydiabetes mellitusdorsal root ganglionnerve injury-specific long non-coding RNAnerve traumaneuropathic pain

Identifiers

PMID36460518
PMCPMC9997083
OpenAlexW4309918246

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.